PART I Overview We are a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. MASH was previously known as nonalcoholic steatohepatitis (NASH). MASH is the leading cause of liver transplantation in women, the second leading cause of all liver transplantation ...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-19 | 2025-12-31 | 0001628280-26-009514 | EDGAR | 84K words |
| 2025-02-26 | 2024-12-31 | 0001628280-25-007980 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0001628280-24-007376 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001193125-23-045575 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001193125-22-051569 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001193125-21-056164 | EDGAR | — |
| 2020-02-26 | 2019-12-31 | 0001193125-20-049021 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001047469-19-000725 | EDGAR | — |
| 2018-03-13 | 2017-12-31 | 0001047469-18-001557 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001047469-17-002260 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-30 | 2026-06-30 | 0001628280-26-050845 | EDGAR | — |
| 2025-11-04 | 2025-09-30 | 0001628280-25-048559 | EDGAR | 22K words |
| 2025-08-05 | 2025-06-30 | 0001628280-25-037613 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001628280-25-021356 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001628280-24-044445 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001628280-24-035400 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001628280-24-020865 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001193125-23-270803 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001193125-23-205535 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001193125-23-138863 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001193125-22-276468 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001193125-22-211757 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-30 | 0001628280-26-050775 | EDGAR | — |
| 2026-02-19 | 0001628280-26-009476 | EDGAR | 2K words |
| 2026-01-30 | 0001104659-26-008698 | EDGAR | — |
| 2025-12-11 | 0001628280-25-056533 | EDGAR | — |
| 2025-11-04 | 0001628280-25-048525 | EDGAR | — |
| 2025-08-05 | 0001628280-25-037596 | EDGAR | — |
| 2025-07-30 | 0001104659-25-071928 | EDGAR | — |
| 2025-07-22 | 0001628280-25-035506 | EDGAR | — |
| 2025-06-20 | 0001628280-25-032358 | EDGAR | — |
| 2025-05-01 | 0001628280-25-021314 | EDGAR | — |
288 total filings indexed. 256 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001157601 |
| Ticker | MDGL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.madrigalpharma.com |
| Listed | 2007-02-06 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/MDGL (~200 tokens, structured JSON with cryptographic provenance)